Melevodopa/carbidopa (Sirio) vs Parcopa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Melevodopa/carbidopa (Sirio)

Marketed by Chiesi Farmaceutici

Phase 1/2 in Parkinson's Diseasesmall molecule
Partial signal

NCT00491998 · Phase 1/2 · completed

The study was randomized and double-blind, with a planned enrollment of 27 participants and a comparison with standard levodopa/carbidopa tablets. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

to characterise the plasma concentrations of L-dopa after repeated doses of V1512 in fluctuating PD patients compared to standard L-dopa/carbidopa (Sinemet) over the course of the day (4 weeks): L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. (not_applicable)

Result source: NCT00491998

Parcopa

Rights held by UCB; US product discontinued

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT00139867 · Phase 3 · completed

The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)

Result source: NCT00139880

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMelevodopa/​carbidopa (Sirio)Parcopa
OFF time, change—Not reported—Not posted · NCT00139880
ON time without troublesome dyskinesia, change—Not reported—Not posted · NCT00139880
UPDRS Part III, change—Not reported—Not posted · NCT00139880
MDS-UPDRS Part II, change—Not reported—Not posted · NCT00139880

OFF time, change

Melevodopa/​carbidopa (Sirio)
—Not reported
Parcopa
—Not posted · NCT00139880

ON time without troublesome dyskinesia, change

Melevodopa/​carbidopa (Sirio)
—Not reported
Parcopa
—Not posted · NCT00139880

UPDRS Part III, change

Melevodopa/​carbidopa (Sirio)
—Not reported
Parcopa
—Not posted · NCT00139880

MDS-UPDRS Part II, change

Melevodopa/​carbidopa (Sirio)
—Not reported
Parcopa
—Not posted · NCT00139880
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Melevodopa/carbidopa (Sirio)
L-dopa accumulation from first to final dose across Cohorts 1/2/3: mean AUC0-t increase V1512 51%/50%/85% vs standard L-dopa/carbidopa 92%/93%/150%; mean Cmax increase V1512 30%/14%/52% vs standard 64%/23%/99%. NCT00491998 · Phase 1/2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Melevodopa/carbidopa (Sirio): 0 of 4 rows · Parcopa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricParcopa
Dropout rate
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00590122 · Phase 4 · registry result, not featured evidence
Serious AEs
0%a
NCT00590122 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
dyskinesia 5%
nausea 0%
NCT00590122 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Parcopa

Time to 'ON Response 23.9 vs 28.5 Carbidopa/Levodopa minutes
absolute value · minutes
NCT00590122 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Melevodopa/carbidopa (Sirio)'s landscape · Parcopa's landscape